Peter E Vaillancourt

US Patent:

6841357, Jan 11, 2005

Filed:

Mar 29, 2002

Appl. No.:

10/113547

Inventors:

Peter Edward Vaillancourt - Del Mar CA, US
Vivian Qingqing Zhang - San Diego CA, US

Assignee:

Stratagene California - La Jolla CA

International Classification:

C12Q 102

US Classification:

435 29, 435 4, 435975

Abstract:

A method of titering adeno-associated virus particles in a sample, said method comprising the steps of contacting target cells with a DNA synthesis inhibitor and an agent that increases the activity of the CMV immediate early promoter; contacting target cells treated as in step (a) with a sample containing adeno-associated virus particles; and determining the number of target cells infected by said adeno-associated virus particles in said sample, wherein said number of target cells infected is directly proportional to the titer of said particles in said sample, thereby determining the titer if said adeno-associated virus particles.

US Patent:

6884620, Apr 26, 2005

Filed:

Aug 29, 2003

Appl. No.:

10/652703

Inventors:

Joseph A. Sorge - Wilson WY, US
Peter Edward Vaillancourt - Del Mar CA, US

International Classification:

C12N005/10
C12N001/00
C12N015/12
C12N015/63

US Classification:

435325, 435243, 4353201, 435419, 536 235

Abstract:

The present invention provides a polynucleotide encoding a green fluorescent protein from comprising a humanized sequence which permits enhanced expression of the encoded polypeptide in mammalian cells.

US Patent:

6936428, Aug 30, 2005

Filed:

Dec 13, 2001

Appl. No.:

10/021818

Inventors:

Ronald W. Davis - Palo Alto CA, US
Peter Vaillancourt - Del Mar CA, US

Assignee:

Stratagene California - La Jolla CA

International Classification:

G01N033/53
C12P021/02
C07K014/00
C07H021/04

US Classification:

435 721, 435 71, 435 72, 530350, 536 234

Abstract:

The invention relates to proteins or polypeptides that comprise intramolecular dimers of fluorescent protein monomers. More specifically, the invention relates to recombinant polypeptides comprising a monomer of a fluorescent polypeptide, a linker peptide, and a second monomer of that fluorescent polypeptide, where the monomers form an intramolecular dimer. The invention also relates to nucleic acids encoding Intramolecular Dimer Fluorescent Proteins (IDFPs) and vectors comprising such nucleic acids. The invention further relates to methods of making IDFPs and methods of using them. IDFPs are, useful in any application suited for fluorescent proteins and are particularly useful in applications in which more than one fluorescent protein sharing complementary dimerization interfaces is present in the same mixture or is expressed in the same cell, because IDFPs do not form heterodimers.

US Patent:

7619069, Nov 17, 2009

Filed:

Oct 19, 2007

Appl. No.:

11/874952

Inventors:

Julian Davies - San Diego CA, US
Craig Duane Dickinson - San Diego CA, US
David Matthew Marquis - Encinitas CA, US
Ying Tang - San Diego CA, US
Peter Edward Vaillancourt - Del Mar CA, US

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

C07K 16/00
A61K 39/395

US Classification:

5303871, 4241301

Abstract:

TGF-beta 1 binding compositions and reagents related thereto are provided. Methods of using such compositions for therapeutic purpose are also provided.

US Patent:

7892546, Feb 22, 2011

Filed:

May 7, 2009

Appl. No.:

12/436925

Inventors:

Cindy Takeuchi Dickerson - San Diego CA, US
David Matthew Marquis - Encinitas CA, US
Victor H. Obungu - Fishers IN, US
Peter Edward Vaillancourt - Del Mar CA, US

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 39/00
A61K 39/395
C07K 16/00
C12P 21/08

US Classification:

4241331, 4241391, 4241411, 4241431, 4241441, 5303871, 5303873, 5303879, 5303881, 53038815, 53038822

Abstract:

The present invention provides antibodies that bind human CXCR4 and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful in the treatment of tumorigenesis, including tumor growth, invasion, angiogenesis, or metastasis.

US Patent:

8003102, Aug 23, 2011

Filed:

Dec 17, 2010

Appl. No.:

12/971057

Inventors:

Cindy Takeuchi Dickerson - San Diego CA, US
David Matthew Marquis - Encinitas CA, US
Victor H Obungu - Fishers IN, US
Peter Edward Vaillancourt - Del Mar CA, US

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 39/395
A61K 39/00
C07K 16/00
C12P 21/08

US Classification:

4241411, 4241391, 4241431, 5303871, 5303873, 5303879, 5303881, 53038822

Abstract:

The present invention provides antibodies that bind human CXCR4 and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful in the treatment of tumorigenesis, including tumor growth, invasion, angiogenesis, or metastasis.

US Patent:

8128927, Mar 6, 2012

Filed:

Oct 15, 2009

Appl. No.:

12/579447

Inventors:

Julian Davies - San Diego CA, US
Craig Duane Dickinson - San Diego CA, US
David Matthew Marquis - Encinitas CA, US
Ying Tang - San Diego CA, US
Peter Edward Vaillancourt - Del Mar CA, US

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 39/395

US Classification:

4241301

Abstract:

TGF-beta 1 binding compositions and reagents related thereto are provided. Methods of using such compositions for therapeutic purpose are also provided.

US Patent:

8217148, Jul 10, 2012

Filed:

Nov 18, 2009

Appl. No.:

12/620617

Inventors:

Julian Davies - La Jolla CA, US
Ling Liu - Carmel IN, US
Jirong Lu - Carmel IN, US
Peter Edward Vaillancourt - Del Mar CA, US
Mark Andrew Wortinger - Greenwood IN, US
Wei Zeng - Carmel IN, US

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

C07K 16/00

US Classification:

5303871, 5303888

Abstract:

Provided are monoclonal antibodies, antigen-binding fragments thereof, and combinations of the foregoing, that bind to, and inhibit the activity of, c-Met, and that are effective in treating cancers and other diseases, disorders, or conditions where pathogenesis is mediated by c-Met.